Constantine, G. D., Simon, J. A., Kaunitz, A. M., Pickar, J. H., Revicki, D. A., Graham, S., . . . Mirkin, S. (2020). TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial. Menopause.

Constantine, Ginger D., James A. Simon, Andrew M. Kaunitz, James H. Pickar, Dennis A. Revicki, Shelli Graham, Brian Bernick, and Sebastian Mirkin. "TX-001HR Is Associated With a Clinically Meaningful Effect On Severity of Moderate to Severe Vasomotor Symptoms in the REPLENISH Trial." Menopause 2020.

Constantine, Ginger D., et al. "TX-001HR Is Associated With a Clinically Meaningful Effect On Severity of Moderate to Severe Vasomotor Symptoms in the REPLENISH Trial." Menopause 2020.